Skip to main content
SpringerLink
Log in

Impfung bei erwachsenen Patienten mit chronisch entzündlichen rheumatischen Erkrankungen

Vaccination in adult patients with chronic inflammatory rheumatic diseases

  • Originalien
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Bei Patienten mit chronisch entzündlich rheumatischen Erkrankungen besteht häufig eine intrinsische und therapiebedingte erhöhte Infektanfälligkeit, die wesentlich zu Morbidität und Mortalität der Patienten beiträgt. Ein großer Anteil dieser Infektionen ist impfpräventabel. Aus diesem Grund empfahl die Ständige Impfkommission (STIKO) 2005 neben den Regelimpfungen zusätzlich altersunabhängig bei Patienten mit Immunsuppression die Impfung gegen Pneumokokken, Influenza sowie gegen Haemophilus influenzae b und Meningokokken. Jeder Patient sollte deshalb vor der Einleitung einer immunsuppressiven Therapie über eine mögliche Zunahme der Infektneigung und die empfohlene Impfprävention aufgeklärt werden.

Abstract

Patients with chronic inflammatory rheumatic diseases often have an intrinsic and therapy associated increased susceptibility to infections which substantially contributes to morbidity and mortality of the patients. A large proportion of these infections are preventable by vaccination. For this reason in 2005 the standing vaccination committee (STIKO) recommended for patients with immunosuppression vaccination against pneumococcus, influenza, Haemophilus influenza b and meningococcus in addition to standard vaccinations, independent of age. Every patient should therefore be informed about a possible increase in susceptibility to infections and the recommended prevention by vaccination before implementation of immunosuppressive therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Luis A de, Pigrau C, Pahissa A et al (1990) Infections in 96 cases of systemic lupus erythematosus. Med Clin (Barc) 94(16):607–610

    Google Scholar 

  2. Massardo L, Martinez ME, Baro M et al (1991) Infections in systemic lupus erythematosus. Rev Med Chil 119(10):1115–1122

    PubMed  CAS  Google Scholar 

  3. Oh HM, Chng HH, Boey ML, Feng PH (1993) Infections in systemic lupus erythematosus. Singapore Med J 34(5):406–408

    PubMed  CAS  Google Scholar 

  4. Shyam C, Malaviya AN (1996) Infection-related morbidity in systemic lupus erythematosus: a clinico-epidemiological study from northern India. Rheumatol Int 16(1):1–3

    Article  PubMed  CAS  Google Scholar 

  5. Paton NI (1997) Infections in systemic lupus erythematosus patients. Ann Acad Med Singapore 26(5):694–700

    PubMed  CAS  Google Scholar 

  6. Feuchtenberger M, Kleinert S, Schwab S et al (2011) Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int 32(6):1533–1539

    Article  PubMed  Google Scholar 

  7. Fahy WA, Farnworth E, Yeldrem KP et al (2006) Pneumococcal and influenza vaccination in patients with rheumatic conditions and receiving DMARD therapy. Rheumatology (Oxford) 45(7):912–913

    Google Scholar 

  8. Pradeep J, Watts R, Clunie G (2007) Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 66(6):837–838

    Article  PubMed  Google Scholar 

  9. Koutsogeorgopoulou L, Antoniadis C, Vassilopoulos D, Kassimos D (2009) Preventive influenza vaccination for patients with rheumatoid arthritis. A need for an international campaign. Clin Rheumatol 28(1):103–104

    Article  PubMed  CAS  Google Scholar 

  10. Stojanovich L (2006) Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol 13(2–4):373–375

    Google Scholar 

  11. Duchet-Niedziolka P, Launay O, Coutsinos Z et al (2009) Vaccination in adults with auto-immune disease and/or drug related immune deficiency: results of the GEVACCIM Delphi survey. Vaccine 27(10):1523–1529

    Article  PubMed  CAS  Google Scholar 

  12. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E et al (2007) Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis 66(10):1384–1387

    Article  PubMed  Google Scholar 

  13. Borte S, Liebert UG, Borte M, Sack U (2009) Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 48(2):144–148

    Google Scholar 

  14. Mota LM, Oliveira AC, Lima RA et al (2009) Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases. Rev Soc Bras Med Trop 42(1):23–27

    Article  PubMed  Google Scholar 

  15. Harpaz R, Ortega-Sanchez IR, Seward JF (2008) Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57(RR-5):1–30

    Google Scholar 

  16. Elkayam O, Amir S, Mendelson E et al (2011) Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 63:1062–1067

    Article  Google Scholar 

  17. Evison J, Farese S, Seitz M et al (2009) Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 48(10):1402–1412

    Article  PubMed  CAS  Google Scholar 

  18. Holvast A, Huckriede A, Wilschut J et al (2006) Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 65(7):913–918

    Article  PubMed  CAS  Google Scholar 

  19. Moberley SA, Holden J, Tatham DP, Andrews RM (2008) Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev (1):CD000422

    Google Scholar 

  20. Centers for Disease Control CDC (2008) Progress in introduction of pneumococcal conjugate vaccine – worldwide, 2000–2008. MMWR Morb Mortal Wkly Rep 57(42):1148–1151

    Google Scholar 

  21. Metlay JP, Fishman NO, Joffe M, Edelstein PH (2006) Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 24(4):468–475

    Article  PubMed  CAS  Google Scholar 

  22. Carvalho JF de, Pereira RM, Shoenfeld Y (2008) Systemic polyarteritis nodosa following hepatitis B vaccination. Eur J Intern Med 19(8):575–578

    Article  PubMed  Google Scholar 

  23. Carmeli Y, Oren R (1993) Hepatitis B vaccine side-effect. Lancet 341(8839):250–251

    Article  PubMed  CAS  Google Scholar 

  24. Elkayam O, Yaron M, Caspi D (2002) Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 61(7):623–625

    Article  PubMed  CAS  Google Scholar 

  25. Mast EE, Weinbaum CM, Fiore AE et al (2006) A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 55(RR-16):1–33

    Google Scholar 

  26. Dengler TJ, Zimmermann R, Meyer J et al (1999) Vaccination against tick-borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients. Vaccine 17(7–8):867–874

    Google Scholar 

  27. Nath R, Mant C, Luxton J et al (2007) High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum 57(4):619–625

    Article  PubMed  CAS  Google Scholar 

  28. Mok CC, Ho LY, Fong LS, To CH (2012) Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis [Epub ahead of print]

  29. Wiese-Posselt M, Hellenbrand W (2010) Changes to the varicella and pertussis immunisation schedule in Germany 2009: background, rationale and implementation. Euro Surveill 15(16)pii:19548

    PubMed  Google Scholar 

  30. Geier DA, King PG, Sykes LK, Geier MR (2008) RotaTeq vaccine adverse events and policy considerations. Med Sci Monit 14(3):H9–H16

    Google Scholar 

  31. Roux A de, Schmole-Thoma B, Siber GR et al (2008) Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 46(7):1015–1023

    Article  PubMed  Google Scholar 

  32. Roux A de, Marx A, Burkhardt O et al (2006) Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine 24(10):1537–1542

    Article  PubMed  Google Scholar 

  33. Kapetanovic MC, Saxne T, Sjoholm A et al (2006) Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 45(1):106–111

    Google Scholar 

  34. Fomin I, Caspi D, Levy V et al (2006) Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 65(2):191–194

    Article  PubMed  CAS  Google Scholar 

  35. Mazzone PJ, Mossad SB, Mawhorter SD et al (2001) The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J 18(6):971–976

    Article  PubMed  CAS  Google Scholar 

  36. Versluis DJ, Beyer WE, Masurel N et al (1986) Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 42(4):376–379

    Article  PubMed  CAS  Google Scholar 

  37. Dengler TJ, Strnad N, Buhring I et al (1998) Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation 66(10):1340–1347

    Article  PubMed  CAS  Google Scholar 

  38. Abu-Shakra M, Press J, Varsano N et al (2002) Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 29(12):2555–2557

    PubMed  CAS  Google Scholar 

  39. Battafarano DF, Battafarano NJ, Larsen L et al (1998) Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 41(10):1828–1834

    Article  PubMed  CAS  Google Scholar 

  40. Salles MJ, Sens YA, Boas LS, Machado CM (2010) Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transplant 24(1): E17–E23

    Article  PubMed  CAS  Google Scholar 

  41. Lipnick RN, Karsh J, Stahl NI et al (1985) Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J Rheumatol 12(6):1118–1121

    PubMed  CAS  Google Scholar 

  42. Kaine JL, Kivitz AJ, Birbara C, Luo AY (2007) Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 34(2):272–279

    PubMed  CAS  Google Scholar 

  43. Mease PJ, Ritchlin CT, Martin RW et al (2004) Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 31:1356–1361

    PubMed  CAS  Google Scholar 

  44. Del PF, Lagana B, Biselli R et al (2006) Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 24(16):3217–3223

    Article  Google Scholar 

  45. Keshtkar-Jahromi M, Argani H, Rahnavardi M et al (2008) Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: a controlled trial. Am J Nephrol 28(4):654–660

    Article  PubMed  CAS  Google Scholar 

  46. Rentenaar RJ, Diepen FN van, Meijer RT et al (2002) Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int 62(1):319–328

    Article  PubMed  CAS  Google Scholar 

  47. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P (2007) Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 46(4):608–611

    Google Scholar 

  48. Visvanathan S, Keenan GF, Baker DG et al (2007) Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 34(5):952–957

    PubMed  CAS  Google Scholar 

  49. Gelinck LB, Bijl AE van der, Beyer WE et al (2008) The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 67(5):713–716

    Article  PubMed  CAS  Google Scholar 

  50. Elkayam O, Bashkin A, Mandelboim M et al (2009) The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 39(6):442–447

    Article  PubMed  Google Scholar 

  51. Gelinck LB, Teng YK, Rimmelzwaan GF et al (2007) Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 66(10):1402–1403

    Article  PubMed  CAS  Google Scholar 

  52. Albert D, Dunham J, Khan S et al (2008) Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 67(12):1724–1731

    Article  PubMed  CAS  Google Scholar 

  53. Horwitz SM, Negrin RS, Blume KG et al (2004) Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103(3):777–783

    Article  PubMed  CAS  Google Scholar 

  54. Bearden CM, Agarwal A, Book BK et al (2005) Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 5(1):50–57

    Article  PubMed  CAS  Google Scholar 

  55. Kolk LE van der, Baars JW, Prins MH, Oers MH van (2002) Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100(6):2257–2259

    PubMed  Google Scholar 

  56. Bingham CO III, Looney RJ, Deodhar A et al (2010) Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 62(1):64–74

    Article  PubMed  CAS  Google Scholar 

  57. van Assen S, Holvast A, Benne CA et al (2010) Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62(1):75–81

    Article  Google Scholar 

  58. Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581

    Article  PubMed  CAS  Google Scholar 

  59. Cambridge G, Leandro MJ, Teodorescu M et al (2006) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54(11):3612–3622

    Article  PubMed  CAS  Google Scholar 

  60. Vallerskog T, Gunnarsson I, Widhe M et al (2007) Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 122(1):62–74

    Article  PubMed  CAS  Google Scholar 

  61. Tay L, Leon F, Vratsanos G et al (2007) Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 9(2):R38

    Article  PubMed  Google Scholar 

  62. Mori S, Ueki Y, Akeda Y et al (2013) Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis 72(8):1362–1366

    Article  PubMed  Google Scholar 

  63. Mori S, Ueki Y, Hirakata N et al (2012) Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 71(12):2006–2010

    Article  PubMed  CAS  Google Scholar 

  64. Elkayam O, Caspi D, Reitblatt T et al (2004) The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33:283–288

    Article  PubMed  CAS  Google Scholar 

  65. Williams GW, Steinberg AD, Reinertsen JL et al (1978) Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med 88(6):729–734

    Article  PubMed  CAS  Google Scholar 

  66. Brodman R, Gilfillan R, Glass D, Schur PH (1978) Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med 88(6):735–740

    Article  PubMed  CAS  Google Scholar 

  67. Louie JS, Nies KM, Shoji KT et al (1978) Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 88(6):790–792

    Article  PubMed  CAS  Google Scholar 

  68. Ristow SC, Douglas RG Jr, Condemi JJ (1978) Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 88(6):786–789

    Article  PubMed  CAS  Google Scholar 

  69. Herron A, Dettleff G, Hixon B et al (1979) Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA 242(1):53–56

    Article  PubMed  CAS  Google Scholar 

  70. Klippel JH, Karsh J, Stahl NI et al (1979) A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum 22:1321–1325

    Article  PubMed  CAS  Google Scholar 

  71. Elkayam O, Paran D, Burke M et al (2005) Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity 38(7):493–496

    Article  PubMed  CAS  Google Scholar 

  72. Kuruma KA, Borba EF, Lopes MH et al (2007) Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 16(5):350–354

    Article  PubMed  CAS  Google Scholar 

  73. Setti M, Fenoglio D, Ansaldi F et al (2009) Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 27(25–26):3367–3372

    Google Scholar 

  74. Mader R, Narendran A, Lewtas J et al (1993) Systemic vasculitis following influenza vaccination – report of 3 cases and literature review. J Rheumatol 20(8):1429–1431

    PubMed  CAS  Google Scholar 

  75. Schattner A (2005) Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 23(30):3876–3886

    Article  PubMed  CAS  Google Scholar 

  76. Holvast A, Stegeman CA, Benne CA et al (2009) Wegener’s granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 68(6):873–878

    Article  PubMed  CAS  Google Scholar 

  77. Stassen PM, Sanders JS, Kallenberg CG, Stegeman CA (2008) Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 23(2):654–658

    Article  PubMed  Google Scholar 

  78. Sahin N, Salli A, Enginar AU, Ugurlu H (2009) Reactive arthritis following tetanus vaccination: a case report. Mod Rheumatol 19(2):209–211

    Article  PubMed  Google Scholar 

  79. Gross K, Combe C, Kruger K, Schattenkirchner M (1995) Arthritis after hepatitis B vaccination. Report of three cases. Scand J Rheumatol 24(1):50–52

    Article  PubMed  CAS  Google Scholar 

  80. Assen S van, Agmon-Levin N, Elkayam O et al (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70:414–422

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

K. Warnatz erhielt Vortragshonorare/Drittmittel von Abbott, Wyeth/Pfizer, Baxter, Octapharma, Merck. S. Goldacker: Drittmittel von Octapharma. A.M. Gause: keine. K. Warnatz wird unterstützt vom Bundesministerium für Bildung und Forschung (BMBF 01 EO 0803). Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Centrum für Chronische Immmundefizienz, Universitätsklinikum Freiburg und Universität Freiburg, Breisacher Str. 117 - 2. OG, 79106, Freiburg, Deutschland

    S. Goldacker & K. Warnatz

  2. Schwerpunktpraxis für Rheumatologie und Autoimmunerkrankungen, Hamburg, Deutschland

    A.M. Gause

Authors
  1. S. Goldacker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A.M. Gause
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Warnatz
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Kommission Pharmakotherapie der DGRh

Corresponding author

Correspondence to S. Goldacker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldacker, S., Gause, A., Warnatz, K. et al. Impfung bei erwachsenen Patienten mit chronisch entzündlichen rheumatischen Erkrankungen. Z. Rheumatol. 72, 690–704 (2013). https://doi.org/10.1007/s00393-013-1155-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-013-1155-4

Schlüsselwörter

Keywords

Search

Navigation